Clinical Trials Logo

Clinical Trial Summary

Single-center, observational, prospective cohort study including patients hospitalized on the multidrug-resistant tuberculosis ward at Marius Nasta Institute.

The increasing rates of multidrug-resistant (MDR) tuberculosis (TB) are causing great concern. The current study that will be conducted at the Marius Nasta Institute, one of two nationwide excellence treatment centers for MDR-TB in Romania, is aiming to prospectively investigate the population structure of patients with MDR-TB admitted for treatment and the M. tuberculosis strains isolated from these patients. Transmission of MDR- strains of Mycobacterium tuberculosis among patients hospitalized there will be also ascertained. Additionally biomarkers for treatment response during the course of the tuberculosis therapy will be evaluated.

The study will be conducted in a co-operation between the Marius Nasta Institute and the German Center for Infection Research (DZIF).


Clinical Trial Description

Single-center, observational, prospective cohort study including all patients hospitalized on the MDR-TB ward at Marius Nasta Institute.

An estimated 100 patients with MDR-TB consecutively admitted for treatment at the MNI will be assessed for eligibility as study participants. All potential participants will be asked to provide information on demographic, epidemiological and clinical characteristics as well as prior treatment and disease history. Microbiological data, treatment and adverse events data will also be recorded. The data is expected to supplement the existing body of knowledge about patients with MDR-TB from the region.

In order to characterize M. tuberculosis strains, sputum samples will be collected from the participants upon admission to the MDR-TB ward and after 3 months of therapy. Additionally, subsequent samples identified as being positive after prior culture conversion will also undergo testing. Key examinations on these samples include drug susceptibility testing on solid media and molecular typing. If samples originating from the same patient show discordance, whole genome sequencing will be performed to allow strain comparison between the actual patient strain and those isolated from other patients to identify potential nosocomial transmission. The location on ward of patients as well as their activities will also be recorded in the scope of identifying possible routes of transmission.

Blood and urine samples will be collected at specific time points during the study and further assessed in order to identify candidate biomarkers that are potentially correlated with response to anti-tuberculosis therapy.

All data generated from this study will be collected on standardized study forms and entered in a password-secured database. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02413931
Study type Observational
Source Research Center Borstel
Contact
Status Active, not recruiting
Phase
Start date May 2015
Completion date December 2020

See also
  Status Clinical Trial Phase
Recruiting NCT05871489 - Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Active, not recruiting NCT04179500 - A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers Phase 2
Completed NCT03086486 - Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis Phase 3
Completed NCT01201941 - Operational Assessment of Laboratory Information System for MDR-TB in Lima, Peru N/A
Completed NCT03303963 - DIAgnostics for Multidrug Resistant Tuberculosis in Africa
Recruiting NCT05306223 - A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China Phase 4
Completed NCT02573350 - A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683 Phase 2
Active, not recruiting NCT02597621 - Biomarkers for Therapy Response in Drug-resistant Tuberculosis
Recruiting NCT05555303 - Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis Phase 2
Recruiting NCT03828201 - Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB Phase 2
Recruiting NCT01212003 - Training Protocol on the Natural History of Tuberculosis
Terminated NCT03237182 - The Individualized M(X) Drug-resistant TB Treatment Strategy Study Phase 4
Completed NCT03338621 - Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients Phase 2/Phase 3
Not yet recruiting NCT05007795 - Test to Treat TB: Impact of Sputum Sequencing-guided Individualised Therapy on Outcomes in Drug-resistant Tuberculosis N/A
Completed NCT03728725 - Xpert MTB/XDR Clinical Evaluation Trial
Active, not recruiting NCT02589782 - Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) Phase 2/Phase 3
Recruiting NCT02619994 - Treatment Shortening of MDR-TB Using Existing and New Drugs Phase 2
Completed NCT01918397 - Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB Phase 2
Completed NCT00513396 - High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis Phase 2/Phase 3